发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
Future oral drug options for multiple sclerosis treatment 多发性硬化症治疗的未来口服药物选择
Future Prescriber Pub Date : 2011-01-20 DOI: 10.1002/fps.69
Carolyn Young MD, FRCP
{"title":"Future oral drug options for multiple sclerosis treatment","authors":"Carolyn Young MD, FRCP","doi":"10.1002/fps.69","DOIUrl":"10.1002/fps.69","url":null,"abstract":"<p><b>Multiple sclerosis is a common, chronic and disabling neurological disease with a variable clinical course including relapse and progression. Here the author reviews three promising oral agents, currently in the late stages of development and regulatory approval, for the treatment of MS that appear to reduce the frequency of relapses and improve patient acceptability.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 3","pages":"12-15"},"PeriodicalIF":0.0,"publicationDate":"2011-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.69","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77384791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Boehringer Ingelheim: advances in oncology and diabetes 勃林格殷格翰:在肿瘤和糖尿病领域取得进展
Future Prescriber Pub Date : 2011-01-20 DOI: 10.1002/fps.72
{"title":"Boehringer Ingelheim: advances in oncology and diabetes","authors":"","doi":"10.1002/fps.72","DOIUrl":"https://doi.org/10.1002/fps.72","url":null,"abstract":"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its current portfolio, and look at its pipeline of new drugs and areas of research interest.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 3","pages":"22-23"},"PeriodicalIF":0.0,"publicationDate":"2011-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.72","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137865056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The promise of future treatments in AF: is it all over for warfarin? 心房颤动的未来治疗前景:华法林是否已经结束?
Future Prescriber Pub Date : 2010-07-13 DOI: 10.1002/fps.64
Sotiris Antoniou BPharm (Hons), MSc, DipMgt
{"title":"The promise of future treatments in AF: is it all over for warfarin?","authors":"Sotiris Antoniou BPharm (Hons), MSc, DipMgt","doi":"10.1002/fps.64","DOIUrl":"10.1002/fps.64","url":null,"abstract":"<p>Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 2","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2010-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.64","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90260873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of chronic pain: current and future options 慢性疼痛的管理:当前和未来的选择
Future Prescriber Pub Date : 2010-07-13 DOI: 10.1002/fps.65
Robert Searle FRCA, Karen Simpson FRCA FFPMRCA
{"title":"Management of chronic pain: current and future options","authors":"Robert Searle FRCA,&nbsp;Karen Simpson FRCA FFPMRCA","doi":"10.1002/fps.65","DOIUrl":"10.1002/fps.65","url":null,"abstract":"<p>Chronic pain is surprisingly prevalent and, if left untreated, can lead to significant limitations for the sufferer including restricted mobility and possible job loss. Pain has also been shown to be the reason for 40% of patient visits to GPs each year. This results in a substantial economic burden not only for those involved but also for the wider economy. Here we review the current options for pain management and look at new treatments in the pipeline. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 2","pages":"11-14"},"PeriodicalIF":0.0,"publicationDate":"2010-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.65","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75491391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Novartis: new developments in multiple sclerosis and oncology 诺华:多发性硬化症和肿瘤学的新进展
Future Prescriber Pub Date : 2010-07-13 DOI: 10.1002/fps.67
{"title":"Novartis: new developments in multiple sclerosis and oncology","authors":"","doi":"10.1002/fps.67","DOIUrl":"https://doi.org/10.1002/fps.67","url":null,"abstract":"<p>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Novartis and its current portfolio, and look at its pipeline of new drugs and areas of research interest. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 2","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2010-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.67","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137512804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost of shingles to patients and the NHS: hope on the horizon? 带状疱疹对患者和NHS的成本:希望在地平线上?
Future Prescriber Pub Date : 2010-07-13 DOI: 10.1002/fps.66
Joanna Lumb
{"title":"Cost of shingles to patients and the NHS: hope on the horizon?","authors":"Joanna Lumb","doi":"10.1002/fps.66","DOIUrl":"10.1002/fps.66","url":null,"abstract":"<p>Shingles carries a considerable burden to patients and to the health service. The expected introduction of routine shingles vaccination raises hope for reducing this debilitating infection and its complications. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 2","pages":"15-17"},"PeriodicalIF":0.0,"publicationDate":"2010-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.66","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77062365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prescribing options for leukaemia in the spotlight at ASH 2009 白血病的处方选择是2009年ASH会议的焦点
Future Prescriber Pub Date : 2010-03-15 DOI: 10.1002/fps.63
Stephen Pinn
{"title":"Prescribing options for leukaemia in the spotlight at ASH 2009","authors":"Stephen Pinn","doi":"10.1002/fps.63","DOIUrl":"10.1002/fps.63","url":null,"abstract":"<p>UK doctors figured prominently during the clinical sessions at the 51st annual meeting of the American Society of Hematology (ASH) held in New Orleans, December 4-8, 2009, which attracted a worldwide audience of more than 25 000 blood disorder and oncology specialists. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 1","pages":"18-19"},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.63","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90048434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New directions in cancer therapy - HDAC inhibitors 癌症治疗的新方向——HDAC抑制剂
Future Prescriber Pub Date : 2010-03-15 DOI: 10.1002/fps.60
Stephen Schey FRCP, FRACP, FRCPath
{"title":"New directions in cancer therapy - HDAC inhibitors","authors":"Stephen Schey FRCP, FRACP, FRCPath","doi":"10.1002/fps.60","DOIUrl":"10.1002/fps.60","url":null,"abstract":"<p>The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 1","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.60","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88642492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COPD management: new and existing therapy options 慢性阻塞性肺病管理:新的和现有的治疗方案
Future Prescriber Pub Date : 2010-03-15 DOI: 10.1002/fps.62
David Price MA, MRCGP, DRCOG, Rhonda Siddall
{"title":"COPD management: new and existing therapy options","authors":"David Price MA, MRCGP, DRCOG,&nbsp;Rhonda Siddall","doi":"10.1002/fps.62","DOIUrl":"10.1002/fps.62","url":null,"abstract":"<p>Early detection and appropriate management of chronic obstructive pulmonary disease (COPD) may help to reduce the high mortality and morbidity associated with this disease. New pharmacological treatments for COPD, along with the implementation of recommendations of the National Strategy for COPD due for publication later this year, will help to raise the standard of care and improve outcomes for COPD patients. In this article, Professor Price and Rhonda Siddall consider current COPD therapy and look at future treatment options for COPD. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 1","pages":"12-16"},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.62","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84743091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Grünenthal: developing and expanding in pain research grental:疼痛研究的发展和扩展
Future Prescriber Pub Date : 2010-03-15 DOI: 10.1002/fps.61
{"title":"Grünenthal: developing and expanding in pain research","authors":"","doi":"10.1002/fps.61","DOIUrl":"https://doi.org/10.1002/fps.61","url":null,"abstract":"<p>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Grünenthal and its current portfolio, and look at the current pipeline and areas of research interest. Copyright © 2010 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 1","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.61","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137525872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信